Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Leap Therapeutics, Inc. (LPTX)

0.6407   -0.029 (-4.33%) 01-27 16:00
Open: 0.7 Pre. Close: 0.6697
High: 0.7099 Low: 0.6303
Volume: 343,913 Market Cap: 63(M)

Technical analysis

as of: 2023-01-27 4:46:04 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.92     One year: 1.07
Support: Support1: 0.54    Support2: 0.4
Resistance: Resistance1: 0.78    Resistance2: 0.92
Pivot: 0.57
Moving Average: MA(5): 0.65     MA(20): 0.54
MA(100): 0.74     MA(250): 1.16
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 60.5     %D(3): 62.2
RSI: RSI(14): 57.9
52-week: High: 2.56  Low: 0.4
Average Vol(K): 3-Month: 836 (K)  10-Days: 1,685 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LPTX ] has closed below upper band by 29.3%. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.71 - 0.72 0.72 - 0.72
Low: 0.62 - 0.63 0.63 - 0.63
Close: 0.63 - 0.64 0.64 - 0.65

Company Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Headline News

Sat, 28 Jan 2023
Leap Therapeutics (NASDAQ:LPTX) PT Lowered to $3.00 - MarketBeat

Thu, 26 Jan 2023
Mergers and Acquisitions in 2023 Off To A Strong Start - MarketBeat

Tue, 24 Jan 2023
LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the ... - Business Wire

Mon, 23 Jan 2023
SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO ... - PR Newswire

Mon, 23 Jan 2023
SHAREHOLDER ALERT: Weiss Law Investigates Evoqua Water ... - PR Newswire

Mon, 23 Jan 2023

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 99 (M)
% Held by Insiders 7.562e+007 (%)
% Held by Institutions 9.2 (%)
Shares Short 2,380 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -5.237e+007
EPS Est Next Qtl -0.63
EPS Est This Year -3.17
EPS Est Next Year -3.09
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -13
Return on Assets (ttm) 970.6
Return on Equity (ttm) -31.2
Qtrly Rev. Growth 375000
Gross Profit (p.s.) 0
Sales Per Share -98.32
EBITDA (p.s.) 2.58621e+006
Qtrly Earnings Growth -0.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -47 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0.4
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.52

Stock Dividends

Dividend 0
Forward Dividend 2.2e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.